Having identified renin in cardiac mast cells, we assessed whether its release leads to cardiac dysfunction. In Langendorff-perfused guinea pig hearts, mast cell degranulation with compound 48/80 released Ang I–forming activity. This activity was blocked by the selective renin inhibitor BILA2157, indicating that renin was responsible for Ang I formation. Local generation of cardiac Ang II from mast cell–derived renin also elicited norepinephrine release from isolated sympathetic nerve terminals. This action was mediated by Ang II-type 1 (AT1) receptors. In 2 models of ischemia/reperfusion using Langendorff-perfused guinea pig and mouse hearts, a significant coronary spillover of renin and norepinephrine was observed. In both models, this was accompanied by ventricular fibrillation. Mast cell stabilization with cromolyn or lodoxamide markedly reduced active renin overflow and attenuated both norepinephrine release and arrhythmias. Similar cardioprotection was observed in guinea pig hearts treated with BILA2157 or the AT1 receptor antagonist EXP3174. Renin overflow and arrhythmias in ischemia/reperfusion were much less prominent in hearts of mast cell–deficient mice than in control hearts. Thus, mast cell–derived renin is pivotal for activating a cardiac renin-angiotensin system leading to excessive norepinephrine release in ischemia/reperfusion. Mast cell–derived renin may be a useful therapeutic target for hyperadrenergic dysfunctions, such as arrhythmias, sudden cardiac death, myocardial ischemia, and congestive heart failure.
Christina J. Mackins, Seiichiro Kano, Nahid Seyedi, Ulrich Schäfer, Alicia C. Reid, Takuji Machida, Randi B. Silver, Roberto Levi
Title and authors | Publication | Year |
---|---|---|
A Retinoic Acid β 2 -Receptor Agonist Exerts Cardioprotective Effects
A Marino, T Sakamoto, XH Tang, LJ Gudas, R Levi |
The Journal of pharmacology and experimental therapeutics | 2018 |
Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr 192 and compromises its cardioprotective activity
I Kareinen, M Baumann, SD Nguyen, K Maaninka, A Anisimov, M Tozuka, M Jauhiainen, M Lee-Rueckert, PT Kovanen |
Journal of lipid research | 2018 |
Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition
M Panahi, A Papanikolaou, A Torabi, JG Zhang, H Khan, A Vazir, MG Hasham, JG Cleland, NA Rosenthal, SE Harding, S Sattler |
Cardiovascular Research | 2018 |
Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis
J Zhang, WK Cai, Z Zhang, P Wang, XQ Lin, J Feng, SC Fu, GH He |
Medicine | 2018 |
Use of histamine H2 receptor antagonists and outcomes in patients with heart failure: a nationwide population-based cohort study
K Adelborg, J Sundbøll, M Schmidt, HE Bøtker, NS Weiss, L Pedersen, HT Sørensen |
Clinical epidemiology | 2018 |
Neostigmine-induced coronary spasm: Beware of Kounis syndrome
Xiaofei Yang, Xiaozhi Feng, Feiru Duan, Zhiyong Wang, Monish S Raut, Baryon Swain |
Journal of Anaesthesiology, Clinical Pharmacology | 2018 |
Mast Cells: Key Contributors to Cardiac Fibrosis.
Levick SP, Widiapradja A |
International journal of molecular sciences | 2018 |